$XBI $67.87 | -5.02%
Table of Contents:
Covid Updates
$TNXP -13.1% Tonix Pharmaceuticals Extends Research Collaboration with the University of Alberta to Develop Antiviral Drugs Against SARS-CoV-2. source
Pipeline Updates
$ENTA -17.3% Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV) source
$SRNE -3.8% Scilex, a Sorrento Company, Announces Initiation of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 in Subjects with Acute Low Back Pain. source
$VSTM +0.9% Verastem Oncology Awarded Pancreatic Cancer Action Network’s First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer. source
$LEGN -2.9% Legend Biotech to Highlight Continued Progress in the Treatment of Multiple Myeloma With Updated Data From BCMA CAR-T Studies at 2022 ASCO and EHA. source
$ALDX -6.8% Aldeyra Therapeutics Announces that Post-Hoc Analysis Using Computer Automated Grading of Phase 3 TRANQUILITY Trial Digital Photography Demonstrated Statistical Significance in Favor of Reproxalap Over Vehicle for Primary Endpoint of Ocular Redness. source
$RAIN -1.4% Rain Therapeutics to Present on Milademetan at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. source
$SEEL -5.5% Seelos Therapeutics Receives a Notice of Allowance in the U.S. for an Additional Patent for SLS-007. source
$AVTX +6.8% Avalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma (NEA). source
$CYTK -8.3% Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS. source
$MRNA -3.2% IAVI and Moderna Launch First-in-Africa Clinical Trial of mRNA HIV Vaccine Development Program. source
$AXSM -7.3% Axsome Therapeutics Announces Publication of Pivotal ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder in The American Journal of Psychiatry. source
$IMTX -2.8% Immatics Announces First Patient Treated with ACTengine® IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo® (nivolumab) in Patients with Advanced Solid Tumors. source
$DTIL -5.8% Precision BioSciences Announces Publication in Molecular Therapy of ARCUS® In Vivo Gene Editing as a Promising Therapeutic Approach to Cure Chronic Hepatitis B Infection. source
$CABA -13.3% Cabaletta Bio Presents Updated Interim DesCAARTesâ„¢ Trial Phase 1 Data at the ASGCT 25th Annual Meeting. source
$EDIT -7.8% Editas Medicine Presents Data on SLEEK Gene Editing Technology at the American Society of Gene and Cell Therapy Annual Meeting. source
$SQZ -0.6% SQZ Biotechnologies Announces Integrated Point-of-Care Cell Therapy Manufacturing System Demonstrated Comparable or Better Performance Than a More Conventional Clean Room-Based Process. source
$FIXX -6.6% Homology Medicines Presents Details of Optimized HMI-103 Nuclease-Free Gene Editing Candidate Featuring Integrated Liver-Specific Promoter to Maximize Long-Term Expression. source
$KROS -16.6% Keros Therapeutics Announces Preliminary Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating KER-012 in Healthy Volunteers. source
Want to get weekly catalyst updates?
*We never spam you - unsubscribe anytime*
Business Updates
$ORPH -3.7% Restructuring Proposal. source
$AMTI -18.5% Applied Molecular Transport Provides Strategy Update. source
Posted by FS/JM